This review summarizes current evidence and emerging therapeutic strategies across four evolving areas: menin inhibition, <i>FLT3</i> inhibition, <i>IDH</i> inhibition and treatment approaches for <i>TP53</i>-mutated AML.<h4>Methods</h4>We reviewed published clinical trials, preclinical studies, and ongoing clinical trials evaluating targeted therapies in AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.